About Lightpoint Medical
Lightpoint Medical develops and markets miniaturized imaging and sensing tools for intra-operative cancer detection. The company is addressing the urgent medical challenge that despite technological advances in robotic platforms, surgeons lack the tools to accurately detect cancer intra-operatively. As a result, cancer is often left behind or more healthy tissue than needed is removed, increasing the need for adjuvant therapies, causing post-surgical complications, and escalating healthcare costs.
Ad Statistics
Times Displayed: 366918
Times Visited: 7172 Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576
Lightpoint has a pipeline of miniaturized surgical tools in development with the first, SENSEI®, recently approved for sale by regulators in the US, EU, UK and Australia. The first commercial focus is prostate cancer surgery with a planned expansion into other solid tumor types.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix's lead investigational product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,[2] and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).[3] Telix is also progressing marketing authorisation applications for Illuccix® in the European Union[4] and Canada.[5] None of Telix's products have received a marketing authorisation in any jurisdiction.
Back to HCB News